Orodispersible Tablet Hardness via API Crystalline Base
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for manufacturing fast disintegrating tablets often result in products with poor tablet strength and low friability, limiting their use of conventional packaging materials and procedures.
Innovation Solution
The development of a process to obtain a pure crystalline escitalopram base, which is then formulated into orodispersible tablets using conventional melt agglomeration or extrusion processes, ensuring high tablet strength and low friability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional melt granulation or foam techniques are used to manufacture fast disintegrating tablets, then the tablets can disintegrate quickly in the mouth, but the tablet strength becomes poor and friability increases
Solution Approach 1:
The patent changes the physical-chemical parameters of the active pharmaceutical ingredient by selecting compounds with specific melting points (40-100°C) and utilizing their phase transition properties. This allows the API to serve as both the active ingredient and a binding agent, achieving rapid disintegration while maintaining adequate tablet strength through controlled melting and solidification during compression
Solution Approach 2:
The patent makes the active pharmaceutical ingredient multi-functional by using it as both the therapeutic agent and the binding material in the tablet formulation. The API with melting point 40-100°C serves dual purposes: providing the desired rapid disintegration property and contributing to tablet structural integrity, thereby eliminating the need for separate binding agents that would compromise strength
2Duration of action of moving object
If unconventional equipment and complicated processing techniques such as lyophilization and foam techniques are used, then fast disintegrating tablets can be produced, but the manufacturing process becomes complex and equipment requirements increase
Solution Approach 1:
The patent extracts and eliminates the need for complex unconventional equipment by utilizing the inherent properties of the active pharmaceutical ingredient itself. By selecting compounds with appropriate melting points and using them as binding agents, the process can be performed with conventional tablet compression equipment, removing the requirement for specialized lyophilization apparatus or foam generation systems
Solution Approach 2:
The active pharmaceutical ingredient performs self-service by utilizing its own physical properties (melting point 40-100°C) to achieve the desired tablet disintegration characteristics. The API binds the tablet matrix together through its phase transition behavior, eliminating the need for external binding agents or complex processing equipment, and allowing standard manufacturing equipment to produce the final product
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enables the production of orodispersible tablets with a hardness of at least 22 N and an oral-disintegration time of less than 120 seconds, using conventional equipment and techniques, thereby overcoming the limitations of previous methods.
Implementation Method 1
an active pharmaceutical ingredient adsorbed onto a water-soluble filler
Implementation Method 2
by crystallising the base, and thereafter optionally forming a salt from the base
Data Source
AI summary
The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts. Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100° C., as well as a method for making such an orodispersible tablet.